Heron Therapeutics
Update in progressHRTX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Heron Therapeutics, Inc. is a commercial‑stage biotech company using Biochronomer, a drug‑delivery technology that sustains therapeutic levels from a single dose. It markets SUSTOL (granisetron) for chemo‑induced nausea and CINVANTI (aprepitant) for PONV and CINV. It is developing ZYNRELEF (bupivacaine/meloxicam) and APONVIE (IV aprepitant). Formerly A.P. Pharma, renamed 2014. Founded 1983, based in Cary, NC.
Company score
- Sentiment
- 0.18
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.10
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!